Beta Bionics IncBBNX
Price$18.87Intrinsic value$18.991% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $119M+82.7% YoYTTM through 30 Jun 2026
Net Income -$73MTTM through 30 Jun 2026
Free Cash Flow -$61.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin59.5%
EBITDA Margin-68.5%
Operating Margin-88.0%
Net Margin-61.3%

Returns

-8.1%ROE
-22.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.69x
Net Debt-$206.4Mnet cash position
Cash & Equivalents$44.3M

Quality Metrics

Altman Z-Score18.32
Piotroski F-Score3 / 9
FCF Margin-51.6%
Rule of 40-39.6
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $100.3M
Diluted EPS-$1.60TTM
'23'24'25
FY2025: $-1.81

Dividend

No dividend

Capital Allocation

R&D Spend$38.9M
Capex Intensity4.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.